Clinical Trial Update: Ranibizumab Supplementing Panretinal Photocoagulation as Treatment for Iris/Angle Neovascularization in Retinal Ischemic Disease [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update of ranibizumab added to panretinal photocoagulation for iris/angle neovascularization in retinal ischemic disease; Phase 1 and Phase 2 tri…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Retinal Ischemia

Drugs mentioned

• Lucentis (ranibizumab)

Snippet

Sponsor: Southern New England Retina Associates | Conditions: Retinal Ischemia | Phase 1, Phase 2 | Status: COMPLETED